Form 13-F position report

ROYALTY PHARMA PLC

Reported by NEW SOUTH CAPITAL MANAGEMENT INC

RPRX CUSIP G7709Q104 Manager CIK 0001044797

Reported 1,445,493 shares, down 940,450 (39.4%) from the prior quarter.

Reported value -36.9%; share count -39.4% vs. the prior quarter.

Reduced
% of reported 13F value 5.5% This manager · Q3 2026
Shares 1,445,493 Quarter-end amount reported
Reported value $84,358,971 Fair value at quarter end
Consecutive quarters held 11 Through Q3 2026

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2024-03-31 44384388
2024-06-30 61942523
2024-09-30 69773645
2024-12-31 75436259
2025-03-31 90509510
2025-06-30 104003081
2025-09-30 102956319
2025-12-31 113167982
2026-03-31 125962648
2026-06-30 133779824
2026-09-30 84358971

Quarterly position history

How this manager's reported quarter-end position changed over time.

11 quarters
Quarterly reported position history for ROYALTY PHARMA PLC held by NEW SOUTH CAPITAL MANAGEMENT INC.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 Reduced 1,445,493 -940,450 (-39.4%) 5.5% $84,358,971 2026-11-05
Q2 2026 Reduced 2,385,943 -239,920 (-9.1%) 5.87% $133,779,824 2026-08-10
Q1 2026 Reduced 2,625,863 -302,915 (-10.3%) 6.04% $125,962,648 2026-05-13
Q4 2025 Added 2,928,778 +10,515 (0.4%) 5.21% $113,167,982 2026-02-12
Q3 2025 Added 2,918,263 +31,694 (1.1%) 4.69% $102,956,319 2025-11-06
Q2 2025 Reduced 2,886,569 -20,900 (-0.7%) 5.04% $104,003,081 2025-08-13
Q1 2025 Reduced 2,907,469 -49,656 (-1.7%) 4.36% $90,509,510 2025-04-28
Q4 2024 Added 2,957,125 +490,754 (19.9%) 3.18% $75,436,259 2025-02-06
Q3 2024 Added 2,466,371 +117,394 (5.0%) 2.85% $69,773,645 2024-11-05
Q2 2024 Added 2,348,977 +887,522 (60.7%) 2.77% $61,942,523 2024-08-06
Q1 2024 New 1,461,455 +1,461,455 (0.0%) 1.86% $44,384,388 2024-05-07

Who else reported the position

752 managers reported ROYALTY PHARMA PLC for Q3 2026.

Managers reporting ROYALTY PHARMA PLC in Q3 2026.
Manager Activity Shares Change % of reported 13F Reported value Tenure
MORGAN STANLEY Reduced 41,100,185 -1,831,412 0.12% $2,398,606,956 26 qtrs
Capital International Investors Reduced 33,897,019 -1,376,751 0.41% $1,978,230,029 6 qtrs
BlackRock Inc Added 29,117,396 +1,284,419 0.03% $1,699,291,230 9 qtrs
FMR LLC Reduced 19,348,880 -5,164,934 0.05% $1,129,200,661 26 qtrs
PRICE T ROWE ASSOCIATES INC MD Added 14,712,137 +3,518,480 0.09% $858,601,000 26 qtrs
STATE STREET CORPORATION Added 12,951,600 +613,371 0.02% $755,855,376 26 qtrs
Swedbank AB Reduced 10,260,593 -466,015 0.51% $598,808,207 22 qtrs
BAILLIE GIFFORD & CO Reduced 9,151,948 -863,630 0.5% $534,107,685 19 qtrs
Capital World Investors Reduced 8,755,768 -761,569 0.06% $510,986,620 3 qtrs
GEODE CAPITAL MANAGEMENT LLC Added 8,546,758 +488,710 0.03% $497,512,565 26 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2026
Filed
November 05, 2026
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
1,147,513
Shared
0
None
297,980

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.